ClinicalTrials.gov
public full text
Public Domain
Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes
A study to evaluate the efficacy and safety of Human Insulin Inhalation Powder \[also known as AIR® Inhaled Insulin\]\[AIR® is a registered trademark of Alkermes,Inc.\] in patients with Type 2 diabetes who are currently being treated with once daily insulin glargine injections. The present study is intended to determine if mealtime AIR® Insulin may be superior to once-daily insulin glargine injections.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma#897893
- Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD#1072783
- This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus#918451
- Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes#141205
- Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes#1060880
Record · ID 899279
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive